Karol Zbroński
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karol Zbroński has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Zenon Huczek
Medical University of Warsaw
13 shared publications - Janusz Kochman
First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
12 shared publications Grzegorz Opolski
1st Department of Cardiology, Medical University of Warsaw, Warszawa, Poland
11 shared publicationsBartosz Rymuza
1st Department of Cardiology, Medical University of Warsaw, Warszawa, Poland
10 shared publicationsPiotr Scisło
1st Department of Cardiology, Medical University of Warsaw, Warszawa, Poland
10 shared publicationsRadosław Wilimski
Department of Cardiac Surgery, Medical University of Warsaw, Warszawa, Poland
9 shared publications
Latest Publications
- 30 September 2021
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 79 (9) , 995-1002
Protamine sulfate during transcatheter aortic valve implantation (PS TAVI) — a single-center, single-blind, randomized placebo-controlled trial
Bleeding complications after transcatheter aortic valve implantation (TAVI) negatively affect the post-procedural prognosis. Routine use of protamine sulfate (PS) to reverse unfractionated heparin after TAVI was never assessed in a randomized controlled trial. The aim of this study was to assess the impact of PS on bleeding complications after TAVI. Between December 2016 and July 2020 311 patients qualified to TAVI in one academic center were screened. Patients that met the inclusion criteria were randomized to either PS or normal saline administration at the moment of optimal valve deployment. Baseline, procedural, and follow-up data for up to 30 days were collected and analyzed. The primary endpoint (PE) was a composite of life-threatening and major bleeding according to Valve Academic Research Consortium within 48 hours after the procedure. Overall, 100 patients (48 males, median age 82 years) met the inclusion criteria and were included in the study. Forty-seven subjects (47%) were randomized to PS. The primary endpoint occurred in 29% of the study population. Despite numerically lower rates of PE in patients randomized to PS, a statistical significance was not reached (21% in the PS group and 36% in the placebo group; odds ratio [OR], 0.48; 95% confidence intervals [CI] 0.2-1.2; P = 0.11). There were no significant differences in secondary endpoints. Routine protamine sulfate administration did not significantly decrease the rate of major and life-threatening bleeding complications after TAVI. Larger studies are required to assess the impact of routine PS use.
- 30 September 2021
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 79 (9) , 995-1002
Protamine sulfate during transcatheter aortic valve implantation (PS TAVI) — a single-center, single-blind, randomized placebo-controlled trial
Bleeding complications after transcatheter aortic valve implantation (TAVI) negatively affect the post-procedural prognosis. Routine use of protamine sulfate (PS) to reverse unfractionated heparin after TAVI was never assessed in a randomized controlled trial. The aim of this study was to assess the impact of PS on bleeding complications after TAVI. Between December 2016 and July 2020 311 patients qualified to TAVI in one academic center were screened. Patients that met the inclusion criteria were randomized to either PS or normal saline administration at the moment of optimal valve deployment. Baseline, procedural, and follow-up data for up to 30 days were collected and analyzed. The primary endpoint (PE) was a composite of life-threatening and major bleeding according to Valve Academic Research Consortium within 48 hours after the procedure. Overall, 100 patients (48 males, median age 82 years) met the inclusion criteria and were included in the study. Forty-seven subjects (47%) were randomized to PS. The primary endpoint occurred in 29% of the study population. Despite numerically lower rates of PE in patients randomized to PS, a statistical significance was not reached (21% in the PS group and 36% in the placebo group; odds ratio [OR], 0.48; 95% confidence intervals [CI] 0.2-1.2; P = 0.11). There were no significant differences in secondary endpoints. Routine protamine sulfate administration did not significantly decrease the rate of major and life-threatening bleeding complications after TAVI. Larger studies are required to assess the impact of routine PS use.
- Open Access
- 1 January 2020
- Published by Termedia Sp. z.o.o. in Advances in Interventional Cardiology
- Vol. 16 (3) , 306-314
Use of protamine sulfate during transfemoral transcatheter aortic valve implantation - a preliminary assessment of administration rate and impact on complications
Introduction: Bleeding complications after transcatheter aortic valve implantation (TAVI) are an important issue and negatively affect survival. The rate and impact of protamine sulfate (PS) administration on bleeding complications after TAVI remain unclear. Aim: To assess the impact of PS on bleeding complications after TAVI. Material and methods: Between March 2010 and November 2016 two hundred fifty-eight patients qualified for TAVI in one academic center were screened. Baseline, procedural and follow-up data up to 30 days were collected and analyzed. The primary endpoint (PE) was major bleeding according to the Valve Academic Research Consortium up to 48 h after the procedure. Results: Overall, 186 patients (96 females, mean age: 80 years) met the inclusion criteria. Thirty-nine (21%) subjects received PS. PE occurred in 24.7% of the study population. There were no significant differences in terms of the PE rate between the groups (25.6% in the PS group and 24.7% in the remaining cohort, p = 0.9, odds ratio (OR) = 1.05, confidence interval (CI): 0.47-2.4, p = 0.9). Multivariate analysis identified female gender (OR = 2.2, CI: 1.08-4.4, p = 0.03) as an independent predictor of PE occurrence. Similarly, female gender (OR = 2, CI: 1.06-3.84, p = 0.03) as well as general anesthesia (GA, OR = 2.23, CI: 1.13-4.63, p = 0.02) and dose of unfractionated heparin per kilogram (UFH/kg, OR = 1.02, CI: 1-1.03 per 1 IU increment, p = 0.02) predicted the occurrence of a composite of major and minor bleeding. Conclusions: In this analysis, PS administration did not decrease the PE rate. Female gender predicted PE occurrence. Randomized, placebo-controlled trials are required to accurately assess the impact of PS.
- 1 January 2020
- Published by Termedia Sp. z.o.o. in Advances in Interventional Cardiology
- Vol. 16 (3) , 306-314
Open AccessUse of protamine sulfate during transfemoral transcatheter aortic valve implantation - a preliminary assessment of administration rate and impact on complications
Introduction: Bleeding complications after transcatheter aortic valve implantation (TAVI) are an important issue and negatively affect survival. The rate and impact of protamine sulfate (PS) administration on bleeding complications after TAVI remain unclear. Aim: To assess the impact of PS on bleeding complications after TAVI. Material and methods: Between March 2010 and November 2016 two hundred fifty-eight patients qualified for TAVI in one academic center were screened. Baseline, procedural and follow-up data up to 30 days were collected and analyzed. The primary endpoint (PE) was major bleeding according to the Valve Academic Research Consortium up to 48 h after the procedure. Results: Overall, 186 patients (96 females, mean age: 80 years) met the inclusion criteria. Thirty-nine (21%) subjects received PS. PE occurred in 24.7% of the study population. There were no significant differences in terms of the PE rate between the groups (25.6% in the PS group and 24.7% in the remaining cohort, p = 0.9, odds ratio (OR) = 1.05, confidence interval (CI): 0.47-2.4, p = 0.9). Multivariate analysis identified female gender (OR = 2.2, CI: 1.08-4.4, p = 0.03) as an independent predictor of PE occurrence. Similarly, female gender (OR = 2, CI: 1.06-3.84, p = 0.03) as well as general anesthesia (GA, OR = 2.23, CI: 1.13-4.63, p = 0.02) and dose of unfractionated heparin per kilogram (UFH/kg, OR = 1.02, CI: 1-1.03 per 1 IU increment, p = 0.02) predicted the occurrence of a composite of major and minor bleeding. Conclusions: In this analysis, PS administration did not decrease the PE rate. Female gender predicted PE occurrence. Randomized, placebo-controlled trials are required to accurately assess the impact of PS.
- Open Access
- 2 September 2019
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 109 (5) , 570-580
Transcatheter aortic valve implantation in patients with bicuspid aortic valve stenosis utilizing the next-generation fully retrievable and repositionable valve system: mid-term results from a prospective multicentre registry
Background The aim of this study was to evaluate the outcomes of transcatheter aortic valve implantation (TAVI) in bicuspid aortic valve (BiAV) stenosis using a mechanically expanded Lotus™ device. The prior experience with first-generation devices showed disappointing results mainly due to increased prevalence of aortic regurgitation (AR) that exceeded those observed in tricuspid stenosis. Methods and results We collected baseline, in-hospital, 30-day and 2-year follow-up data from a prospective, multicentre registry of patients with BiAV undergoing TAVI using Lotus™ valve. Safety and efficacy endpoints were assessed according to VARC-2 criteria. The study group comprised 24 patients. The mean age was 73.5 years and the mean EuroSCORE 2 was 4.35 ± 2.56%. MDCT analysis revealed Type 1 BiAV in 75% of patients. The mean gradient decreased from 60.1 ± 18.3 to 15 ± 6.4 mm Hg, the AVA increased from 0.6 ± 0.19 to 1.7 ± 0.21 cm2. One in-hospital death was observed secondary to aortic perforation. There was no severe AR and the rate of moderate AR equalled 9% at 30 days (n = 2). Device success was achieved in 83% and the 30-day safety endpoint was 17%. In the 2-year follow-up, the overall mortality was 12.5% and the 2-year composite clinical efficacy endpoint was met in 25% of the patients (n = 6) Conclusions The TAVI in selected BiAV patients using the Lotus™ is feasible and characterized by encouraging valve performance and mid-term clinical outcomes. Graphic abstract
- 2 September 2019
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 109 (5) , 570-580
Open AccessTranscatheter aortic valve implantation in patients with bicuspid aortic valve stenosis utilizing the next-generation fully retrievable and repositionable valve system: mid-term results from a prospective multicentre registry
Background The aim of this study was to evaluate the outcomes of transcatheter aortic valve implantation (TAVI) in bicuspid aortic valve (BiAV) stenosis using a mechanically expanded Lotus™ device. The prior experience with first-generation devices showed disappointing results mainly due to increased prevalence of aortic regurgitation (AR) that exceeded those observed in tricuspid stenosis. Methods and results We collected baseline, in-hospital, 30-day and 2-year follow-up data from a prospective, multicentre registry of patients with BiAV undergoing TAVI using Lotus™ valve. Safety and efficacy endpoints were assessed according to VARC-2 criteria. The study group comprised 24 patients. The mean age was 73.5 years and the mean EuroSCORE 2 was 4.35 ± 2.56%. MDCT analysis revealed Type 1 BiAV in 75% of patients. The mean gradient decreased from 60.1 ± 18.3 to 15 ± 6.4 mm Hg, the AVA increased from 0.6 ± 0.19 to 1.7 ± 0.21 cm2. One in-hospital death was observed secondary to aortic perforation. There was no severe AR and the rate of moderate AR equalled 9% at 30 days (n = 2). Device success was achieved in 83% and the 30-day safety endpoint was 17%. In the 2-year follow-up, the overall mortality was 12.5% and the 2-year composite clinical efficacy endpoint was met in 25% of the patients (n = 6) Conclusions The TAVI in selected BiAV patients using the Lotus™ is feasible and characterized by encouraging valve performance and mid-term clinical outcomes. Graphic abstract
- Open Access
- 29 July 2019
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 48 (4) , 610-618
Pre-procedural abnormal function of von Willebrand Factor is predictive of bleeding after surgical but not transcatheter aortic valve replacement
Both transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) have been proven to effectively correct von Willebrand Factor (vWF) pathologies, however there is limited data simultaneously comparing outcomes of both approaches. We prospectively enrolled patients with severe aortic stenosis referred for TAVI (n = 52) or SAVR (n = 48). In each case, vWF antigen (vWF:Ag), vWF activity (vWF:Ac) and activity-to-antigen (vWF:Ac/Ag) ratio were assessed at baseline, 24 h and 72 h after procedure. VWF abnormalities were defined as reduced vWF:Ac/Ag ratio (< 0.8). Bleeding events in both arms were classified according to Valve Academic Research Consortium (VARC-2) definitions. Overall, there was no difference between patients referred for TAVI and SAVR in vWF:Ac (1.62 ± 0.52 vs 1.71 ± 0.64; p = 0.593), vWF:Ag (1.99 ± 0.81 vs 2.04 ± 0.81; p = 0.942) or vWF:Ac/Ag ratio (0.84 ± 0.16 vs 0.85 ± 0.12; p = 0.950). Pathological vWF:Ac/Ag ratio was found in 20 (38%) TAVI and 15 (31%) SAVR patients (p = 0.407). Normalization of vWF:Ac/Ag ratio at day 3 after procedure was achieved in 19 (95%) TAVI and 13 (87%) SAVR patients (p = 0.439). Similar prevalence of major or life-threatening bleedings (MLTB) after TAVI and SAVR in entire groups was observed (19% vs. 23%, p = 0.652). VWF abnormalities were associated with higher incidence of MLTB in SAVR (53% vs 9%, p < 0.001), but not TAVI (15% vs. 22%, p = 0.132). Accordingly, in receiver-operating characteristic curve analysis vWF:Ac/Ag ratio < 0.8 showed significant sensitivity and specificity for predicting MLTB in SAVR group (AUC 0.735, 95% CI 0.538–0.931, p = 0.019). We proved that abnormal function of vWF is corrected successfully after both TAVI and SAVR, but vWF abnormalities are predictive of MLTB only in surgical patients.
- 29 July 2019
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 48 (4) , 610-618
Open AccessPre-procedural abnormal function of von Willebrand Factor is predictive of bleeding after surgical but not transcatheter aortic valve replacement
Both transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) have been proven to effectively correct von Willebrand Factor (vWF) pathologies, however there is limited data simultaneously comparing outcomes of both approaches. We prospectively enrolled patients with severe aortic stenosis referred for TAVI (n = 52) or SAVR (n = 48). In each case, vWF antigen (vWF:Ag), vWF activity (vWF:Ac) and activity-to-antigen (vWF:Ac/Ag) ratio were assessed at baseline, 24 h and 72 h after procedure. VWF abnormalities were defined as reduced vWF:Ac/Ag ratio (< 0.8). Bleeding events in both arms were classified according to Valve Academic Research Consortium (VARC-2) definitions. Overall, there was no difference between patients referred for TAVI and SAVR in vWF:Ac (1.62 ± 0.52 vs 1.71 ± 0.64; p = 0.593), vWF:Ag (1.99 ± 0.81 vs 2.04 ± 0.81; p = 0.942) or vWF:Ac/Ag ratio (0.84 ± 0.16 vs 0.85 ± 0.12; p = 0.950). Pathological vWF:Ac/Ag ratio was found in 20 (38%) TAVI and 15 (31%) SAVR patients (p = 0.407). Normalization of vWF:Ac/Ag ratio at day 3 after procedure was achieved in 19 (95%) TAVI and 13 (87%) SAVR patients (p = 0.439). Similar prevalence of major or life-threatening bleedings (MLTB) after TAVI and SAVR in entire groups was observed (19% vs. 23%, p = 0.652). VWF abnormalities were associated with higher incidence of MLTB in SAVR (53% vs 9%, p < 0.001), but not TAVI (15% vs. 22%, p = 0.132). Accordingly, in receiver-operating characteristic curve analysis vWF:Ac/Ag ratio < 0.8 showed significant sensitivity and specificity for predicting MLTB in SAVR group (AUC 0.735, 95% CI 0.538–0.931, p = 0.019). We proved that abnormal function of vWF is corrected successfully after both TAVI and SAVR, but vWF abnormalities are predictive of MLTB only in surgical patients.
- 18 April 2019
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 77 (4) , 482-483
Percutaneous retrograde paramitral leak closure through a mechanical aortic valve
- 18 April 2019
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 77 (4) , 482-483
Percutaneous retrograde paramitral leak closure through a mechanical aortic valve
- 21 December 2018
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 29 (2) , 256-258
Percutaneous pulmonary valve implantation in patients after Ross procedure: role of intravascular ultrasound
Coronary compression exclusion during right ventricle outflow tract stenting is recommended and potential oversight may be fatal. Balloon inflation in right ventricle outflow tract with simultaneous aortography can be inconclusive or falsely negative. We present a case of 27-year-old male post Ross operation qualified for percutaneous pulmonary valve implantation. Neither of the conventional views obtained provided a definite exclusion of coronary compression, therefore an intravascular ultrasound of the left coronary artery before and during balloon inflation in right ventricle outflow tract was performed. Acquired images allowed excluding potential constriction, thus a covered stent and pulmonary valve were implanted and the procedure was concluded. Two hours later, the patient complained of chest pain. Transthoracic echocardiography demonstrated a significant pericardial effusion. Retrospective analysis of the final angiogram revealed a possibility of subtle extravasation at the distal part of the homograft. A hybrid procedure consisting of additional covered stent implantation, pericardial drainage, and second pulmonary valve implantation was performed with an acceptable result. To conclude, in case of doubtful or unconvincing images obtained from aortography or selective angiography during balloon inflation in right ventricle outflow tract, intravascular ultrasound might be a feasible and useful technique. Signs of homograft rupture may be subtle, whereas symptoms of cardiac tamponade delayed. In selected patients percutaneous treatment of homograft rupture is achievable and beneficial.
- 21 December 2018
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 29 (2) , 256-258
Percutaneous pulmonary valve implantation in patients after Ross procedure: role of intravascular ultrasound
Coronary compression exclusion during right ventricle outflow tract stenting is recommended and potential oversight may be fatal. Balloon inflation in right ventricle outflow tract with simultaneous aortography can be inconclusive or falsely negative. We present a case of 27-year-old male post Ross operation qualified for percutaneous pulmonary valve implantation. Neither of the conventional views obtained provided a definite exclusion of coronary compression, therefore an intravascular ultrasound of the left coronary artery before and during balloon inflation in right ventricle outflow tract was performed. Acquired images allowed excluding potential constriction, thus a covered stent and pulmonary valve were implanted and the procedure was concluded. Two hours later, the patient complained of chest pain. Transthoracic echocardiography demonstrated a significant pericardial effusion. Retrospective analysis of the final angiogram revealed a possibility of subtle extravasation at the distal part of the homograft. A hybrid procedure consisting of additional covered stent implantation, pericardial drainage, and second pulmonary valve implantation was performed with an acceptable result. To conclude, in case of doubtful or unconvincing images obtained from aortography or selective angiography during balloon inflation in right ventricle outflow tract, intravascular ultrasound might be a feasible and useful technique. Signs of homograft rupture may be subtle, whereas symptoms of cardiac tamponade delayed. In selected patients percutaneous treatment of homograft rupture is achievable and beneficial.
- 1 October 2018
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 14 (8) , 894-895
Main pulmonary artery perforations after left atrial appendage occluder implantation
- 1 October 2018
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 14 (8) , 894-895
Main pulmonary artery perforations after left atrial appendage occluder implantation
- 16 February 2018
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 76 (2) , 418-425
Thromboelastography for predicting bleeding in patients with aortic stenosis treated with transcatheter aortic valve implantation
Background and aims: Bleeding complications are frequent and independently impact mortality after TAVI. Thromboelastography (TEG) measures viscoelastic properties of clot formation and is currently best known for perioperative management to reduce blood transfusion in cardiac surgery. We sought to determine whether TEG may be predictive of bleeding in patients treated with TAVI. Methods and results: Overall, 54 consecutive patients with severe aortic stenosis treated with TAVI were prospectively included. In all patients, 2 blood samples were obtained for TEG measurement (1st - 12h prior to procedure tested with Citrated Kaolin [CK] TEG assay, and the 2nd - immediately after prosthesis deployment tested with CK and Citrated Kaolin Heparinised assay [CKH]). Major or life-threatening bleeding (MLTB) was diagnosed in 13 (24%) patients. In receiver-operating characteristic (ROC) curve analysis the only TEG parameters showing significant sensitivity and specificity for predicting MLTB were those obtained in the CK sample at the end of the procedure: R value (reaction time, time to initiation of clot formation) AUC 0.69, 95% confidence intervals (CI) 0.49-0.88, P=0.04; Angle (the rate of clot formation), AUC 0.75, 95%CI 0.59-0.92, P=0.007 and MA (maximum amplitude, ultimate strength of fibrin clot), AUC 0.77, 95%CI 0.62-0.93, P=0.003. After controlling for confounding factors in multivariate logistic regression, MA remained as the only TEG parameter which significantly correlated with bleeding after TAVI, both as a continuous variable (P=0.004; 95%CI 0.92-0.98; OR 0.95 per 1mm increment) and after using the cut-off value derived from ROC analysis; MA P=0.004; OR 10.4; 95%CI 2.1-51.8). Conclusions: Low strength of fibrin clot measured by TEG immediately after TAVI may serve as an independent predictor of short-term major and life-threatening bleeding complications. Background and aims: Bleeding complications are frequent and independently impact mortality after TAVI. Thromboelastography (TEG) measures viscoelastic properties of clot formation and is currently best known for perioperative management to reduce blood transfusion in cardiac surgery. We sought to determine whether TEG may be predictive of bleeding in patients treated with TAVI. Methods and results: Overall, 54 consecutive patients with severe aortic stenosis treated with TAVI were prospectively included. In all patients, 2 blood samples were obtained for TEG measurement (1st - 12h prior to procedure tested with Citrated Kaolin [CK] TEG assay, and the 2nd - immediately after prosthesis deployment tested with CK and Citrated Kaolin Heparinised assay [CKH]). Major or life-threatening bleeding (MLTB) was diagnosed in 13 (24%) patients. In receiver-operating characteristic (ROC) curve analysis the only TEG parameters showing significant sensitivity and specificity for predicting MLTB were those obtained in the CK sample at the end of the procedure: R value (reaction time, time to initiation of clot formation) AUC 0.69, 95% confidence intervals (CI) 0.49-0.88, P=0.04; Angle (the rate of clot formation), AUC 0.75, 95%CI 0.59-0.92, P=0.007 and MA (maximum amplitude, ultimate strength of fibrin clot), AUC 0.77, 95%CI 0.62-0.93, P=0.003. After controlling for confounding factors in multivariate logistic regression, MA remained as the only TEG parameter which significantly correlated with bleeding after TAVI, both as a continuous variable (P=0.004; 95%CI 0.92-0.98; OR 0.95 per 1mm increment) and after using the cut-off value derived from ROC analysis; MA P=0.004; OR 10.4; 95%CI 2.1-51.8). Conclusions: Low strength of fibrin clot measured by TEG immediately after TAVI may serve as an independent predictor of short-term major and life-threatening bleeding complications.
- 16 February 2018
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 76 (2) , 418-425
Thromboelastography for predicting bleeding in patients with aortic stenosis treated with transcatheter aortic valve implantation
Background and aims: Bleeding complications are frequent and independently impact mortality after TAVI. Thromboelastography (TEG) measures viscoelastic properties of clot formation and is currently best known for perioperative management to reduce blood transfusion in cardiac surgery. We sought to determine whether TEG may be predictive of bleeding in patients treated with TAVI. Methods and results: Overall, 54 consecutive patients with severe aortic stenosis treated with TAVI were prospectively included. In all patients, 2 blood samples were obtained for TEG measurement (1st - 12h prior to procedure tested with Citrated Kaolin [CK] TEG assay, and the 2nd - immediately after prosthesis deployment tested with CK and Citrated Kaolin Heparinised assay [CKH]). Major or life-threatening bleeding (MLTB) was diagnosed in 13 (24%) patients. In receiver-operating characteristic (ROC) curve analysis the only TEG parameters showing significant sensitivity and specificity for predicting MLTB were those obtained in the CK sample at the end of the procedure: R value (reaction time, time to initiation of clot formation) AUC 0.69, 95% confidence intervals (CI) 0.49-0.88, P=0.04; Angle (the rate of clot formation), AUC 0.75, 95%CI 0.59-0.92, P=0.007 and MA (maximum amplitude, ultimate strength of fibrin clot), AUC 0.77, 95%CI 0.62-0.93, P=0.003. After controlling for confounding factors in multivariate logistic regression, MA remained as the only TEG parameter which significantly correlated with bleeding after TAVI, both as a continuous variable (P=0.004; 95%CI 0.92-0.98; OR 0.95 per 1mm increment) and after using the cut-off value derived from ROC analysis; MA P=0.004; OR 10.4; 95%CI 2.1-51.8). Conclusions: Low strength of fibrin clot measured by TEG immediately after TAVI may serve as an independent predictor of short-term major and life-threatening bleeding complications. Background and aims: Bleeding complications are frequent and independently impact mortality after TAVI. Thromboelastography (TEG) measures viscoelastic properties of clot formation and is currently best known for perioperative management to reduce blood transfusion in cardiac surgery. We sought to determine whether TEG may be predictive of bleeding in patients treated with TAVI. Methods and results: Overall, 54 consecutive patients with severe aortic stenosis treated with TAVI were prospectively included. In all patients, 2 blood samples were obtained for TEG measurement (1st - 12h prior to procedure tested with Citrated Kaolin [CK] TEG assay, and the 2nd - immediately after prosthesis deployment tested with CK and Citrated Kaolin Heparinised assay [CKH]). Major or life-threatening bleeding (MLTB) was diagnosed in 13 (24%) patients. In receiver-operating characteristic (ROC) curve analysis the only TEG parameters showing significant sensitivity and specificity for predicting MLTB were those obtained in the CK sample at the end of the procedure: R value (reaction time, time to initiation of clot formation) AUC 0.69, 95% confidence intervals (CI) 0.49-0.88, P=0.04; Angle (the rate of clot formation), AUC 0.75, 95%CI 0.59-0.92, P=0.007 and MA (maximum amplitude, ultimate strength of fibrin clot), AUC 0.77, 95%CI 0.62-0.93, P=0.003. After controlling for confounding factors in multivariate logistic regression, MA remained as the only TEG parameter which significantly correlated with bleeding after TAVI, both as a continuous variable (P=0.004; 95%CI 0.92-0.98; OR 0.95 per 1mm increment) and after using the cut-off value derived from ROC analysis; MA P=0.004; OR 10.4; 95%CI 2.1-51.8). Conclusions: Low strength of fibrin clot measured by TEG immediately after TAVI may serve as an independent predictor of short-term major and life-threatening bleeding complications.
- 23 January 2018
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 76 (1) , 212
Augmented reality in left atrial appendage occlusion
- 23 January 2018
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 76 (1) , 212
Augmented reality in left atrial appendage occlusion
- 26 August 2017
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 91 (1) , 115-123
Concomitant coronary artery disease and its management in patients referred to transcatheter aortic valve implantation: Insights from the POL‐TAVI Registry
Background: Coronary artery disease (CAD) and degenerative aortic stenosis often coexist. However, the impact of CAD and its management on the prognosis after transcatheter aortic valve implantation (TAVI) remains uncertain. We sought to evaluate the impact of obstructive CAD, SYNTAX score (Ss), and percutaneous coronary intervention (PCI) prior to TAVI on short‐term outcome.Methods: Overall, 896 patients who underwent TAVI after heart team decision was included. Pre‐procedural angiograms were analysed to calculate baseline Ss (bSs) and residual Ss (rSs). Baseline, procedural and follow‐up data up to 30 days was acquired from the national POL‐TAVI registry.Results: Patients with obstructive CAD at baseline (n = 462, 52%) had higher mortality as compared with the remaining (8.7 vs. 5.1%, log‐rank P = 0.039). Also, after correction for confounding factors obstructive CAD was identified as independent predictor of mortality (hazard ratio [HR] 1.74, 95% confidence intervals [CIs] 1.03–2.94, P = 0.037). In obstructive CAD, neither bSs (AUC 0.47, CI 0.38–0.56, P = 0.47) nor rSs (AUC 0.47, CI 0.30–0.64, P = 0.72 for those undergoing PCI and AUC 0.48, CI 0.37–0.59, P = 0.75 for the remaining) was predictive of mortality. When revascularization status was considered, patients with PCI prior to TAVI had similar outcome as those without obstructive CAD at baseline (7.7 vs. 5.1%, log‐rank P = 0.23) with no negative impact on mortality (HR 1.13, CI 0.62–2.09, P = 0.69).Conclusions: In conclusion, obstructive CAD at baseline evaluation for TAVI has independent negative impact on short‐term prognosis. However, neither baseline nor residual Ss values have prognostic ability in patients undergoing TAVI. Revascularization prior to TAVI seems to improve survival to levels comparable with patients without obstructive CAD at baseline.
- 26 August 2017
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 91 (1) , 115-123
Concomitant coronary artery disease and its management in patients referred to transcatheter aortic valve implantation: Insights from the POL‐TAVI Registry
Background: Coronary artery disease (CAD) and degenerative aortic stenosis often coexist. However, the impact of CAD and its management on the prognosis after transcatheter aortic valve implantation (TAVI) remains uncertain. We sought to evaluate the impact of obstructive CAD, SYNTAX score (Ss), and percutaneous coronary intervention (PCI) prior to TAVI on short‐term outcome.Methods: Overall, 896 patients who underwent TAVI after heart team decision was included. Pre‐procedural angiograms were analysed to calculate baseline Ss (bSs) and residual Ss (rSs). Baseline, procedural and follow‐up data up to 30 days was acquired from the national POL‐TAVI registry.Results: Patients with obstructive CAD at baseline (n = 462, 52%) had higher mortality as compared with the remaining (8.7 vs. 5.1%, log‐rank P = 0.039). Also, after correction for confounding factors obstructive CAD was identified as independent predictor of mortality (hazard ratio [HR] 1.74, 95% confidence intervals [CIs] 1.03–2.94, P = 0.037). In obstructive CAD, neither bSs (AUC 0.47, CI 0.38–0.56, P = 0.47) nor rSs (AUC 0.47, CI 0.30–0.64, P = 0.72 for those undergoing PCI and AUC 0.48, CI 0.37–0.59, P = 0.75 for the remaining) was predictive of mortality. When revascularization status was considered, patients with PCI prior to TAVI had similar outcome as those without obstructive CAD at baseline (7.7 vs. 5.1%, log‐rank P = 0.23) with no negative impact on mortality (HR 1.13, CI 0.62–2.09, P = 0.69).Conclusions: In conclusion, obstructive CAD at baseline evaluation for TAVI has independent negative impact on short‐term prognosis. However, neither baseline nor residual Ss values have prognostic ability in patients undergoing TAVI. Revascularization prior to TAVI seems to improve survival to levels comparable with patients without obstructive CAD at baseline.